Vaxart, Inc. (VXRT)

OQX – Real vaqt narxi. Valyuta: USD

0.54

+0.02 (3.85%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

16.06.2026

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Urges Stockholders to Vote “FOR” ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today mailed a letter to shareholders from the Board's two newest independent directors, James Breitmeyer, M.D.

15.06.2026

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA.

09.06.2026

Vaxart to Participate in BTIG Infectious Disease Day 2026

SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the BTIG Infectious Disease Day 2026 on June 16.

08.06.2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Mails Letter to Shareholders Detailing Strength of the Board's Nominees and Momentum in Advancing Vaxart's Value Creation Strategy Reinforces that the Dissident's Nominees Have No Relevant Biotechnology or Public Company Leadership Experience and Their Appointment to the Board Would Be Value Destructive Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today mailed a letter to shareholders urging them to vote “FOR” ALL six of the company's highly qualified director nominees on the WHITE proxy card in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.

01.06.2026

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

19.05.2026

Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.

09.05.2026

Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

16.06.2026

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

15.06.2026

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

09.06.2026

Vaxart to Participate in BTIG Infectious Disease Day 2026

08.06.2026

Vaxart, Inc. (VXRT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vaxart, Inc. (VXRT)

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Search stocks

Vaxart, Inc. (VXRT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vaxart, Inc. (VXRT)

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY